Arcus Biosciences (RCUS) Free Cash Flow (2017 - 2026)

Arcus Biosciences' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$138.0 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 3.76% year-over-year to -$138.0 million; the TTM figure through Mar 2026 stood at -$487.0 million (down 59.15% YoY), while the FY2025 annual figure was -$482.0 million, down 173.86% from the prior year.
• Free Cash Flow was -$138.0 million for Q1 2026 at Arcus Biosciences, down from -$119.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $653.0 million in Q1 2022 to a low of -$138.0 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$39.5 million across 5 years, with a median of -$83.0 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow surged 1045.01% in 2022, then sank 4333.33% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$70.0 million in 2022, then declined by 2.86% to -$72.0 million in 2023, then slumped by 40.28% to -$101.0 million in 2024, then retreated by 17.82% to -$119.0 million in 2025, then dropped by 15.97% to -$138.0 million in 2026.
• The last three Free Cash Flow figures came in at -$138.0 million (Q1 2026), -$119.0 million (Q4 2025), and -$97.0 million (Q3 2025), per Business Quant data.